Many say that personalized medicine is the wave of the future. And biotechnology is without doubt on the cutting edge of medicine. In recent years, biotech drugs have shown increased efficacyand sometimes the power to curefor patients with specific biochemical profiles. Physicians have also started optimizing drug dosages for individual patient metabolisms, improving outcomes while minimizing side effects. Diagnostic testing, which many companies have tried to patent for certain diseases, is the first, critical step in this process.
But the challenge for biotech companies has been to obtain broad patent coverage without claiming a “law of nature,” which is impermissible.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
